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Abstract
Background: It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor
function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive
dysfunction in schizophrenia patients being treated with antipsychotic drugs.
Methods: We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in
which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white
matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated
using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS),
Brief Assessment of Cognition in Schizophrenia (BACS), and other scales.
Results: D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia.
The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms
of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white
matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule
was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the
white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of
D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic
radiation (left) was lower.
Conclusion: It was suggested that response to D-cycloserine is influenced by the onset age and white matter
integrity.
Trial registration: UMIN Clinical Trials Registry (number UMIN000000468). Registered 18 August 2006
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Background
Since N-Methyl-D-aspartate-type glutamate receptor
(NMDA receptor) blockers, including phencyclidine and
ketamine, were clarified to induce schizophrenia-like
positive and negative symptoms and cognitive dysfunc-
tion in proportion to the potency, dysfunction of glu-
tamate neurotransmission through the NMDA receptor
in schizophrenia is assumed [1, 2]. Accordingly, im-
provement of intractable schizophrenia symptoms by en-
hancing the NMDA receptor is expected, and it has
been reported that drugs promoting the NMDA receptor
function by stimulating the glycine modulatory site in
this receptor improved negative symptoms and cognitive
dysfunction in schizophrenia patients being treated with
antipsychotic drugs [3, 4].
D-cycloserine (DCS) was clinically used as an antituber-
culosis drug, but its partial agonist action on the NMDA
receptor glycine modulatory site was newly reported in
1989 [5]. Since then, clinical studies of DCS aiming at im-
provement of schizophrenia symptoms by activating the
NMDA receptor have been performed [6–20]. Compared
with other usable agonists of the glycine modulatory site,
the dose of DCS needed is lower because it readily passes
though the blood-brain barrier, and the dose for psycho-
neurologic disease is about 10–30% of that for tubercu-
losis treatment, being readily clinically applicable. In
several previous clinical studies, the optimum enhance-
ment of the NMDA receptor function can be expected at
about 50 mg/day. Although improvement of negative
symptoms and cognitive dysfunction was reported, the
results of the clinical studies were not consistent. It is pos-
sible that this inconsistency is due to heterogeneity of the
clinical profile among patients analyzed. For example,
early-onset schizophrenia is considered a more severe
form with a poor prognosis [21, 22] and the difference in
the onset age may influence response to treatment, but
these were not investigated in previous studies. In
addition, recent imaging studies suggested that differences
in the brain structure influence the treatment outcome
(reviewed in [23]). To address the influence of illness on-
set and the impact of altered brain structure, in this study,
a placebo-controlled double-blind study of DCS was
performed involving schizophrenia patients, and the
efficacy and its association with the onset age and white




A randomized, placebo-controlled, double-blind, cross-
over design trial was performed at multicenters (Tokyo
Medical and Dental University (TMDU), National Center
of Neurology and Psychiatry, Tokushima University,
Haryugaoka Hospital, Ohmiya Kousei Hospital). We
described this clinical trial according to the CONSORT
2010 guidelines. A 2-week pre-observation period was set
before initiation of drug administration to confirm eligibil-
ity of the subjects, followed by registration and random-
ized allocation. The subsequent 6, 3, and 6 weeks were
established as the first, washout, and second phases, re-
spectively. The rater, medical care staff, subjects, and their
families did not know the allocated test drug, and DCS
(50 mg/day) and placebo (PCB) were prepared with cap-
sules indistinguishable from the appearance. To confirm
the participants’ adherence to the study protocol, blood
levels of DCS were measured by high performance liquid
chromatography (HPLC) with electrochemical detection
in the pre-observation period and at the end of the first
and second phases. The subjects continued taking drugs
that they usually took by the same administration method
and dose throughout the study period.
Inclusion and exclusion criteria
The subjects were patients aged 20 years or older and
below 70 years with schizophrenia meeting the diagnos-
tic criteria of DSM-IV classification regardless of being
in- or outpatients. Patients who received ‘psychotherapy
and formulated cognitive behavioral therapy excluding
supportive psychotherapy’ within 12 weeks, those
diagnosed with substance abuse (alcohol or drug) or
substance dependence within 24 weeks based on the
DSM-IV classification, those who received electrocon-
vulsive therapy within 12 weeks, those with suicide at-
tempt within 24 weeks, those with a past medical history
of or complication by convulsive disease (epilepsy etc.),
those with a past medical history of hypersensitivity to
DCS and lactose, and those with severe organic disorder
of the brain and physical symptoms were excluded.
Participants who smoked were included but no individ-
ual information was obtained. Many participants were
on benzodiazepines and they were maintained on the
same dosage throughout the study. No participant was
on clozapine.
Psychometry
One rater evaluated changes in neurologic manifestations
using the Positive and Negative Syndrome Scale (PANSS)
and Scale for the Assessment of Negative Symptoms
(SANS) every 2 weeks from initiation of the first and sec-
ond phases. The scores before initiation of each phase
were used as baseline scores for each phase. Evaluations
were also made before initiation and after completion of
the first phase and after completion of the second phase
using Brief Assessment of Cognition in Schizophrenia
(BACS), Emotional Intelligence Scale (EQS), Global
Assessment of Functioning (GAF), and the Japanese ver-
sion of the Calgary Depression Scale for Schizophrenia
(JCDSS). In addition, extrapyramidal symptoms were
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evaluated using the Drug Induced Extra-Pyramidal Symp-
toms Scale (DIEPSS) and Abnormal Involuntary Move-
ment Scale (AIMS). The scores before initiation of the
first phase were used as baseline scores for both the first
and second phase. Clinical testing of blood and urine were
also performed to continuously observe the occurrence of
adverse events to evaluate the safety.
Image acquisition
Magnetic resonance (MR) diffusion tensor imaging (DTI)
was performed in the pre-observation period at TMDU.
Imaging data were acquired on the 3.0 T MRI scanner
(3.0 T Signa HDxt, GE Healthcare Japan). Diffusion tensor
images were constructed of 2 sets of diffusion weight axial
slice images (30 directions at b-value = 1000, and a b-
value = 0 s/mm2, slice thickness = 3.0 mm, slice gap = 0,
repetition time = 14,000 ms, echo time = 72.5, matrix
128 × 128 pixels, voxel resolution = 1.875 × 1.875 × 3,
Flip angle = 90°, the number of slices scanned ranged
1600–1800.).
Tract based spatial statistics (TBSS)
To reveal the white matter abnormality in schizophrenia,
statistical analysis was performed using the FSL (FMRIB
Software Library, FMRIB, Oxford, UK) software package
including FDT (FMRIB’s Diffusion Toolbox). First, im-
aging data were collected for the distortion and head
motion, calculated by using the “eddy correct” function.
A brain mask was made from the b = 0 image to use
brain extraction of tensor image, and then fractional an-
isotropy (FA), mean diffusivity (MD), axial diffusivity
(AD), radial diffusivity (RD) maps were calculated by
using the “dtifit” function to fit tensor model. All param-
eters at each voxel were performed by voxel-wise statis-
tics as follows.
Tract based spatial statistics (TBSS) were applied on the
common pseudoanatomical skeleton in which all subjects’
FA data were aligned to FMRIB58_FA standard –space
image, using nonlinear registration tool [24]. And then
atlas based region of interest (ROI) analysis was per-
formed by using JHU DTI 81 labels atlas. This atlas in-
cluded the 48 white matter tracts such as corpus
callosum, fornix, and internal capsule. The voxel mean FA
of these tracts was calculated in each subject.
Statistical analysis
Statistical analysis was performed using the IBM SPSS
Statistics software (version 23.0). The significance level
was set at p < 0.05. Multiple comparison was not taken
into consideration.
Patient characteristics
Difference between the DCS-first and PCB-first groups
on age, age at onset, age at starting therapy, duration of
illness, education, or CPZ equivalents were examined by
Mann-Whitney U-test.
Effect of treatment by time
Three subscales of PANSS (positive symptoms (P), negative
symptoms (N), and general psychopathology (G)) and 7
subscales of SANS (I, II, III, IV, V, summary score, and total
score) were analyzed by 2-way repeated-measures of ana-
lysis of covariance (RM-ANCOVA) constructed of within-
subject factors of treatment (DCS/PCB) and time (baseline,
week 2, week 4, and week 6) and covariates of treatment
order. Seven subscales of BACS (verbal memory (VM),
digit sequencing task (DS), token motor task (TM), sym-
bolic coding (SC), verbal fluency of category (VFC), verbal
fluency of letter (VFL), and tower of London (TOL)) and 3
subscales of EQS (intrapersonal, interpersonal, and situ-
ational domains) were also analyzed using RM-ANCOVA
with a within-subject factor of time (baseline and week 6).
Furthermore, GAF, JCDSS, DIEPSS, and AIMS were
also analyzed using RM-ANCOVA with a within-
subject factor of time (baseline and week 6). If
Mauchly’s sphericity test was significant, then the
Greenhouse-Geisser correction was applied.
Correlation between DCS-effect and DTI white matter
integrity
To investigate whether or not the white matter integrity
influences response to DCS, we first introduced a par-
ameter ‘DCS-effect’ which was defined by scores at DCS
phase subtracted by those at PCB phase. DCS-effect is a
value to indicate the net effect of DCS excluding placebo
effect. Correlations between the tract FA values of the 48
brain regions and DCS-effects on PANSS, SANS, BACS,
and EQS were analyzed using Pearson’s correlation
coefficient. Significance level for the correlation ana-
lysis was set p < 0.01. Multiple comparison was not
taken into consideration.
Secondary analysis: Onset age and DCS-effect
To investigate whether or not the onset age influences
response to DCS, patients were stratified by onset ages
of <18 years (early-onset schizophrenia, EOS) or 18 years
or older (non-early-onset schizophrenia, non-EOS), ac-
cording to the generally accepted threshold for EOS
[25]. Of note, one non-EOS patient was traditionally-
defined late-onset (45 years or older) schizophrenia.
EOS (n = 6) and non-EOS (n = 30) were compared
using multivariate analysis of covariance (MANCOVA)
regarding the DCS-effects on subscales of PANSS (P, N
and G), SANS (I-V, summary and total), BACS (VM, DS,
TM, SC, VFC, VFL, and TOL) and EQS (intrapersonal,
interpersonal, and situational domains) as dependent
variables, onset age (EOS vs. non-EOS) as an independ-
ent variable, and treatment order as a covariate.
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Sample preparation and high-performance liquid
chromatography (HPLC) with electrochemical detection
The concentrations of DCS were quantitated by HPLC
with electrochemical detection according to the method
of Takahashi et al. [26]. For this assay, the plasma sam-
ples provided by the patients were homogenized in 2
volumes of 10% trichloroacetic acid. The supernatants
resulting from centrifugation of the homogenate at
14,500 g for 20 min at 4 °C were neutralized by 2 M imid-
azole and stored at −80 °C until derivatization. An aliquot
of each sample was derivatized with o-phthaldialdehyde
(OPA) (nakalai tesque, Japan) for 2 min at room
temperature. The derivatized sample was immediately
applied to the HPLC system (HTEC-500; EICOM,
Japan) and then analyzed on a on a SC-5ODS
(φ3.0 × 150 mm) with a pre-column. The separation
column was operated at the constant flow rate of
0.5 ml/min at 30 °C. Mobile phase was 50% 50 mM
phosphate buffer solution (pH 2.8) containing 5 mg/L
disodium-ethylenediaminetetraacetic acid (EDTA) and
50% methanol. DCS was eluted in the mobile phase
within 10 min.
The presence of substantial plasma concentrations of
DCS after the actual drug periods, but not the placebo
periods, in each patient was verified.
Results
Patient characteristics
Figure 1 shows the CONSORT diagram for the trial.
Forty-one of 42 patients met the criteria and were en-
rolled in the study. When they were randomly allocated
to the DCS-first (DCS was administered in the first
phase) and PCB-first (PCB was administered in the first
phase) groups, 19 and 22 patients were included in the
groups, respectively. Seventeen (89.5%) and 19 (86.4%)
patients completed the clinical study in the DCS-first
and PCB-first groups, respectively, a total of 36 patients
(Table 1). Five patients dropped out: 2 dropped out (1
each in the DCS-first and PCB-first groups) in the first
treatment phase and 3 dropped out (1 and 2 in the
DCS-first and PCB-first groups, respectively) in the sec-
ond treatment phase. The reason for dropout was an ad-
verse event (liver enzyme elevation) in 2 and poor
compliance of hospital visit in 3. Both cases of adverse
event occurred in the placebo phase.
The male:female ratio of the subjects who completed
the clinical study was 61%:39%, the mean age was
44 years old, the mean age at the time of treatment initi-
ation was 24.4 years old, and the mean duration of ill-
ness was 20.5 years. The mean years of education was
13.2 years, and average chlorpromazine (CPZ) equivalent
Fig. 1 CONSORT flow of participants through the trial
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of antipsychotic drugs they took was 827 mg/day. No
significant difference was noted between the DCS-first
and PCB-first groups on age, age at onset, age at starting
therapy, duration of illness, education, or CPZ equiva-
lents. (Table 1).
The blood DCS levels were measured in each phase
and compared by analysis of variance. There was no dif-
ference between baseline and PCB phase, and a
significant difference between baseline and DCS phase,
indicating that participants were adherent with the study
protocol.
Psychometrics
Effect of treatment by time
No treatment by time effect was noted in any subscale
of PANSS, SANS (Table 2), BACS, or EQS (Table 3). No
Table 1 Patient characteristics
DCS-first group PCB-first group Total
N (Male/Female) 17 (10/7) 19 (12/7) 36 (22/14)
Age (years) 48.4 ± 16.1 40.1 ± 10.7 44.0 ± 14.0
Age at onset (years) 22.6 ± 8.5 24.3 ± 5.6 23.5 ± 7.1
Age at starting therapy (years) 23.9 ± 8.5 24.8 ± 5.7 24.4 ± 7.1
Duration of illness (years) 25.8 ± 17.3 15.8 ± 9.2 20.5 ± 14.4
Education (years) 12.4 ± 2.6 13.9 ± 2.9 13.2 ± 2.9
CPZ equivalents (mg/day) 777.5 ± 614.8 871.3 ± 618.0 827.0 ± 609.5
DCS D-cycloserine, PCB placebo, CPZ chlorpromazine. No significant difference was noted between the DCS-first and PCB-first groups on age, age at onset, age at
starting therapy, duration of illness, education, or CPZ equivalents
Table 2 Treatment by time effect of DCS on PANSS and SANS
Week within treatment phase Analysis
Treatment Baseline Week 2 Week 4 Week 6 treatment x time
Mean SD Mean SD Mean SD Mean SD F p
PANSS
Positive DCS 14.39 5.71 14.42 5.87 14.03 5.86 14.06 5.89 0.51 0.61
PCB 14.72 5.79 14.19 5.46 14.11 5.16 13.97 5.62
Negative DCS 20.47 7.12 20.19 6.97 20.19 6.64 19.86 7.04 0.37 0.69
PCB 20.58 6.87 20.31 7.01 20.00 6.57 19.56 7.11
General DCS 34.44 8.14 33.69 8.36 33.81 8.75 33.56 8.58 1.70 0.18
PCB 35.22 8.11 34.56 7.78 33.97 7.26 33.83 8.48
SANS
I DCS 13.97 8.39 13.56 8.65 13.67 8.51 13.36 8.40 0.34 0.79
PCB 14.03 8.25 13.86 7.88 13.17 7.81 13.44 7.95
II DCS 7.92 4.92 7.39 5.06 7.31 4.83 7.11 4.89 0.44 0.72
PCB 8.22 4.67 7.75 4.78 7.19 4.71 7.22 4.75
III DCS 10.14 4.26 9.89 4.45 9.78 4.32 9.61 4.32 0.50 0.62
PCB 10.00 3.92 9.67 4.24 9.61 4.32 9.78 4.18
IV DCS 12.44 5.34 12.22 5.53 12.08 5.26 12.08 5.44 0.18 0.84
PCB 12.50 5.01 12.33 5.35 12.14 5.16 12.47 5.36
V DCS 5.97 3.61 5.61 3.63 5.44 3.39 4.94 3.43 0.66 0.58
PCB 5.78 3.69 5.64 3.77 4.78 3.39 5.03 3.34
Summary DCS 11.75 4.72 11.33 4.76 11.14 4.59 10.78 4.74 0.79 0.44
PCB 11.42 4.76 11.39 4.56 10.83 4.58 10.89 4.59
Total DCS 50.44 21.88 48.67 22.57 48.28 21.69 47.11 22.55 0.52 0.62
PCB 50.53 20.81 49.25 20.70 46.89 20.42 47.94 20.95
PANSS, Positive and Negative Syndrome Scale; SANS, Scale for the Assessment of Negative Symptoms; SD, standard deviation; ‘Baseline’ indicates Week 0 for the
first phase and Week 9 (after 3 week washout period) for the second phase
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treatment by time effect was noted in any of GAF,
JCDSS, DIEPSS, and AIMS (data not shown).
Differences of DCS-effect by onset age
There was no overall effect of onset age on PANSS sub-
scales (F(3, 31) = 2.20, p = 0.11). However, there was a
significant effect of onset age on negative symptoms
(F(1, 33) = 6.17, p = 0.02) (Table 4). In the non-EOS
group, the scores for both DCS and PCB declined as
time proceeded and almost no difference was noted in
the DCS-effect at 6 W (the score of DCS phase sub-
tracted by the one of PCB phase was −0.07). In the EOS
group, the score for PCB declined as time proceeded
whereas the one for DCS demonstrated less decline or
even an increase, resulting in the positive value for the
DCS-effect at 6 W (the score of DCS phase subtracted
by the one of PCB phase was +2.2) (Fig. 2). No signifi-
cant difference was noted in the overall effect between
EOS and non-EOS on SANS, BACS, or EQS, and no sig-
nificant difference was noted in any subscale. None of
the psychometrics ratings of one patient with late onset
were outliers.
MR diffusion tensor imaging
Data could be collected from 21 of the 36 patients who
completed the study. These participants were those who
agreed and traveled to TMDU for the MRI scan, com-
prising the 3 EOS and 18 non-EOS patients. Regarding
the subscales of PANSS, SANS, BACS, and EQS, the
correlation between the FA value of each brain region
and DCS-effect was investigated (Table 5). The signifi-
cant correlations (p < 0.01) were demonstrated in
PANSS-G, SANS-IV, BACS-TM, and BACS-TOL.
In PANSS-G, an inverse correlation with FA of the
splenium of the corpus callosum was noted (the more
grade of improvement by DCS was associated with
higher FA), and a positive correlation with FA of the
posterior thalamic radiation left (L) was noted (the more
grade of improvement was associated with lower FA).
In SANS-IV, a positive correlation with FA of the pos-
terior thalamic radiation L was noted (the more grade of
improvement was associated with lower FA).
In BACS-TM, positive correlations with FA of the fol-
lowing 4 regions were noted: the sagittal stratum L, cin-
gulum (cingulate gyrus) right (R), cingulum (cingulate
gyrus) L, and fornix stria terminalis R (the more grade
of improvement was associated with higher FA).
In BACS-TOL, positive correlations with FA of the fol-
lowing 5 regions were noted: the genu of corpus callo-
sum, external capsule L, cingulum (cingulate gyrus) R,
cingulum (cingulate gyrus) L, and fornix stria terminalis
L (the more grade of improvement was associated with
higher FA).
Of these significant correlations, if the 3 EOS patients
were excluded from the analysis, the correlations be-
tween BACS-TM and cingulum (cingulate gyrus) R and
BACS-TOL and fornix stria terminalis L turned non-
significant in the p < 0.01 criteria (p = 0.011 and 0.016,
respectively).
Discussion
The main finding of this study was that DCS did not im-
prove positive symptoms, negative symptoms, or cogni-
tive dysfunction of schizophrenia, and these findings
were consistent with most preceding studies concluding
that DCS is ineffective for positive symptoms. Regarding
negative symptoms, the findings were inconsistent with
some preceding studies in which improvement by DCS
was observed [6, 9, 11, 14–16], but consistent with other
preceding studies in which no improvement by DCS was
observed [10, 13, 18–20] or the condition aggravated [7, 8].
Fewer studies evaluated cognitive dysfunction, but the
Table 3 Treatment by time effect of DCS on BACS and EQS
Week within treatment phase Analysis
Treatment Baseline Week 6 treatment x time
Mean SD Mean SD F p
BACS
VM DCS 34.18 15.09 37.15 16.11 0.01 0.91
PCB 37.15 16.04
DS DCS 16.48 5.76 16.97 5.96 0.20 0.65
PCB 17.58 5.84
TM DCS 58.73 21.84 60.64 21.92 0.02 0.90
PCB 63.33 20.69
SC DCS 46.52 16.36 47.03 15.71 0.89 0.35
PCB 48.42 16.21
VFC DCS 15.21 4.70 16.64 6.34 4.06 0.053
PCB 17.24 6.44
VFL DCS 17.55 9.58 18.12 8.23 1.06 0.31
PCB 18.48 8.20
TOL DCS 14.73 5.57 15.70 5.62 0.13 0.72
PCB 16.00 4.33
EQS
intra DCS 39.29 14.40 41.04 18.23 0.08 0.78
PCB 38.75 15.28
inter DCS 38.18 14.54 38.25 15.77 1.53 0.23
PCB 38.75 15.28
situa DCS 30.79 16.89 33.46 18.66 0.00 0.99
PCB 32.36 17.20
BACS Brief Assessment of Cognition in Schizophrenia, VM verbal memory, DS
digit sequencing task, TM token motor task, SC symbolic coding, VFC verbal
fluency of category, VFL verbal fluency of letter, TOL tower of London, EQS
Emotional Intelligence Scale, intra intrapersonal domain, inter interpersonal
domain, situa, situational domain; ‘Baseline’ indicates Week 0 both for the first
and second phase
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condition was unchanged [9–11, 19, 20] excluding a study
reporting an improvement [6], being consistent with our
study. In one meta-analysis including 7 double-blind pla-
cebo controlled studies [27], DCS did not improve any do-
main of symptoms, being consistent with our study.
However, we can’t exclude the possibility that our study
failed to demonstrate significant main effects due to the
lack of statistical power.
It is possible that the absence of the effect of DCS in
this study may have been due to the narrow therapeutic
window of DCS. In a dose finding study in which DCS
was administered to 8 schizophrenia patients at 15, 50,
and 250 mg, negative symptoms were most markedly
improved at 50 mg [6], whereas symptoms aggravated
when DCS was administered at 100 mg or higher [13, 17].
It was assumed that since DCS is a partial agonist, it com-
petes with endogenous glycine for the NMDA receptor
glycine binding site acting as an antagonist. This was the
initial study involving individuals of Japanese descent, and
no Japanese individual may have been included in preced-
ing studies including the dose finding study. It is possible
that DCS 50 mg is not an optimum dose for Japanese and
it may not have changed symptoms in this study.
DCS was administered in addition to antipsychotic
drugs that the patients usually took. In preceding clinical
studies, when DCS was administered to patients usually
treated with clozapine, negative symptoms aggravated
[7, 8]. It has also been reported that the grade of im-
provement of the negative symptom score was greater in
patients usually treated with typical than atypical anti-
psychotic drugs [16]. In the current study, no subject was
medicated with clozapine but most subjects were medi-
cated with atypical antipsychotic drugs, suggesting that
DCS did not exhibit a significant effect on negative symp-
toms in appearance.
DCS was administered at 50 mg/day daily for 6 weeks,
but no improvement of cognitive dysfunction was noted.
According to Goff et al. [11], DCS administered at
50 mg weekly for 8 weeks did not improve overall cogni-
tive function, but improvement was observed in a memory
reconstruction task 7 days after a single administration of
DCS. Regarding the cognitive function, repeated daily ad-
ministration of DCS may cause desensitization of the
Table 4 Differences of DCS-effect by onset age
DCS-effect SD F value p value
PANSS 2.20 0.11
Positive EOS 0.83 1.83 1.54 0.22
non-EOS −0.07 1.39
Negative EOS 2.17 2.79 6.17 0.02
non-EOS −0.07 1.76
General EOS 1.33 3.50 1.72 0.20
non-EOS −0.60 3.07
SANS 1.11 0.38
I EOS 1.50 2.74 2.02 0.16
non-EOS −0.40 2.49
II EOS 0.50 0.84 0.57 0.46
non-EOS −0.23 1.72
III EOS −0.50 1.52 0.20 0.66
non-EOS −0.10 1.60
IV EOS 0.17 1.33 0.54 0.47
non-EOS −0.50 1.81
V EOS 0.67 1.51 0.70 0.41
non-EOS −0.23 1.76
Summary EOS 0.83 1.83 1.95 0.17
non-EOS −0.30 1.51
Total EOS 2.33 5.82 0.92 0.34
non-EOS −1.47 7.22
BACS 0.85 0.56
VM EOS −2.83 9.28 1.64 0.21
non-EOS 0.68 5.12
DS EOS −0.17 2.32 0.19 0.66
non-EOS −0.68 3.42
TM EOS 0.67 5.75 0.47 0.50
non-EOS −3.96 14.86
SC EOS −1.67 6.12 0.01 0.94
non-EOS −1.39 7.02
VFC EOS −3.17 3.54 2.69 0.11
non-EOS 0.04 3.70
VFL EOS 0.67 3.14 0.51 0.48
non-EOS −0.61 5.79
TOL EOS 0.00 3.69 0.02 0.90
non-EOS −0.29 3.75
EQS 1.18 0.34
intra EOS −0.60 12.82 0.86 0.36
non-EOS 2.58 6.10
inter EOS −2.40 9.21 0.65 0.43
Table 4 Differences of DCS-effect by onset age (Continued)
non-EOS 0.17 8.69
situa EOS 3.00 6.12 0.53 0.47
non-EOS 0.79 6.06
PANSS Positive and Negative Syndrome Scale, SANS Scale for the Assessment
of Negative Symptoms, BACS Brief Assessment of Cognition in Schizophrenia,
VM verbal memory, DS digit sequencing task, TM token motor task, SC
symbolic coding, VFC verbal fluency of category, VFL verbal fluency of letter,
TOL tower of London, EQS Emotional Intelligence Scale, intra intrapersonal
domain, inter interpersonal domain, situa situational domain, SD standard
deviation; DCS-effect, scores at DCS phase extracted by those at PCB phase
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NMDA receptor. In animal model, desensitization was ob-
served with repeated daily administration of DCS [28, 29].
Another evidence suggest that elevated co-agonists of
glycine recognition site facilitate the internalization of
NMDA receptor from the cell surface [30], representing
its desensitization. Since DCS was administered daily
repeatedly in our study, it may have caused the
desensitization resulting in the absence of the effect
of DCS on cognitive dysfunction.
The influence of onset age on the DCS-effect was in-
vestigated in the secondary analysis, in which the score
was mostly aggravated in the EOS group compared with
that in the non-EOS group (i.e., the PANSS and SANS
scores increased and the BACS and EQS scores de-
creased) (Table 4), and aggravation of the PANSS score
of negative symptoms in the EOS group was significantly
different from that in the non-EOS group. Generally,
early-onset schizophrenia (EOS) is intractable and the
prognosis is poor compared with non-early-onset
schizophrenia (non-EOS). In addition, in our previous
clinical genetic study in consideration of the onset age,
gene expression related to glutamate neurotransmission
was different between EOS and non-EOS [31]. Findings
observed in these and our studies suggested that heterogen-
eity of the system related to glutamate neurotransmission
appears as a differences in the onset age of schizophrenia
and influences response to treatment. However, the findings
of the current study might be statistically limited due to the
small number of EOS (n = 6) and unbalanced distribution
between EOS and non-EOS (n = 30).
By MR-DTI, evidence of altered FA in brain regions of
the focus of our study has been accumulated, i.e., de-
creased FA in genu and splenium of corpus callosum
has been reported in patients with schizophrenia [32].
Similarly, bilaterally reduced FA was demonstrated in
both anterior and posterior cingulum bundles, and sug-
gested associations between FA and the symptomatology
of schizophrenia [33, 34]. Altered FA was reported in
brain regions including sagittal stratum and external
capsule in suicide attempters with schizophrenia [35].
Reduced FA and increased MD were found in the fornix
of patients with schizophrenia, and increased MD was
associated with performance in cognitive tasks [36]. Al-
though no physiological or pathophysiological signifi-
cance of FA values has been established, it is assumed to
be related to changes in the density and damage of the
white matter. In the current study, a symptom-site-
specific correlation was noted between the treatment ef-
fect of DCS and FA. The better treatment effect of DCS
on BACS was observed when FA was higher in the sagit-
tal stratum, cingulum, fornix stria terminalis, genu of
corpus callosum, and external capsule, and the better
treatment effect on PANSS-G was observed when FA of
the splenium of corpus callosum was higher. In contrast,
the better treatment effect of DCS on PANSS-G and
SANS-IV was observed when FA was lower in the pos-
terior thalamic radiation (left). To our knowledge, there
is no study that has investigated associations between
treatment effect of DCS and white matter integrity. A
study reporting that clozapine treatment increased FA in
various brain regions in patients with schizophrenia is
suggestive to the findings of our study [37]. Although
our study did not examine changes of FA by DCS treat-
ment per se, changes in cells or molecules in the white
matter in the specific brain regions or the grade of sub-
sequent abnormalities of anatomical and functional con-
nectivity between specific brain regions may influence
the treatment effect of DCS. Possible aspects of inter-
preting our findings include that: (1) DCS improves the
cognitive function and PANSS-G when the tract is
retained at a specific level in brain regions other than
the posterior thalamic radiation described above, (2)
changes in connectivity with a part of the cortex closely
connected with the posterior thalamic radiation through
fibers is related the DCS action, and (3) DCS treatment
possibly improved the FA of, e.g. thalamic radiation,
where an asymmetric alteration in the white matter in-
tegrity was demonstrated [38].
Fig. 2 Changes in the scores of PANSS negative symptomPANSS, Positive and Negative Syndrome Scale; DCS-effect was defined by scores at
DCS phase subtracted by those at PCB phase. In the non-EOS group, the scores for both DCS and PCB declined as time proceeded and almost
no difference (−0.07) was noted in the DCS-effect at 6 W. In the EOS group, the score for PCB declined as time proceeded whereas the one for
DCS demonstrated less decline or even an increase, resulting in the positive value (+2.2) for the DCS-effect at 6 W
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Conclusion
In conclusion, DCS did not improve positive symptoms,
negative symptoms, or cognitive dysfunction in schizo-
phrenia. It was suggested that response to DCS is influ-
enced by heterogeneity derived from differences in the
onset age and white matter integrity.
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